Filtros de búsqueda

Lista de obras de Riccardo Danielli

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

artículo científico publicado en 2018

Armed antibodies for cancer treatment: a promising tool in a changing era.

artículo científico publicado en 2014

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.

artículo científico publicado en 2013

Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.

scientific article published on October 2010

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

artículo científico publicado en 2015

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

artículo científico publicado en 2013

Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma.

artículo científico publicado en 2010

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

artículo científico publicado en 2010

Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.

artículo científico publicado en 2011

False Leser-Trélat sign

artículo científico publicado en 2009

ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies.

artículo científico publicado en 2016

Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.

artículo científico

Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.

artículo científico publicado en 2012

Immunotherapy targeting immune check-point(s) in brain metastases

artículo científico publicado en 2017

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

artículo científico publicado en 2015

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.

artículo científico publicado en 2004

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

artículo científico publicado en 2010

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

artículo científico publicado en 2011

Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides

artículo científico publicado en 2012

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

artículo científico publicado en 2013

Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab

artículo científico publicado en 2017

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

artículo científico publicado en 2017

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

artículo científico publicado en 2014

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.

artículo científico

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

artículo científico publicado en 2013